Incyte Corporation: all 314 studies

Page 3 of 4. Open to participants first (38), then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult ParticipantsCompletedNCT06416800Phase 1
• A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host DiseaseActive, not recruitingNCT06388564Phase 2
• A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult FemalesCompletedNCT06380205Phase 1
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT06313593Phase 1
• A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.CompletedNCT06310304Phase 1
• A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib CreamCompletedNCT06213831Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult ParticipantCompletedNCT06213818Phase 1
• A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06212999Phase 3
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Active, not recruitingNCT06113471Phase 3
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Active, not recruitingNCT06113445Phase 3
• Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible UrticariaCompletedNCT06050928Phase 1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT05936359Phase 1
• Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid TumorsTerminatedNCT05909995Phase 1
• A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell CarcinomaTerminatedNCT05888844Phase 2
• A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor NaiveTerminatedNCT05879822Phase 2
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe AsthmaActive, not recruitingNCT05851443Phase 2
• Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHDApproved for marketingNCT05722912
• Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on HemodialysisCompletedNCT05624723Phase 1
• A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedNCT05624710Phase 1
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05620836Phase 3
• A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT05620823Phase 3
• Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced MalignanciesCompletedNCT05577182Phase 1
• Expanded Access of Axatilimab to Treat a Single Patient With Chronic Graft Versus Host Disease (GVHD)Approved for marketingNCT05544032
• Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)Active, not recruitingNCT05429268Phase 3
• INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWithdrawnNCT05359692Phase 2
• Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2WithdrawnNCT05233410Phase 3
• Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1WithdrawnNCT05219864Phase 3
• A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550CompletedNCT05101369Phase 1
• Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and HemodialysisCompletedNCT05099445Phase 1
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707CompletedNCT05068466Phase 1
• Study of Ruxolitinib Cream in Children With Atopic DermatitisCompletedNCT05034822Phase 1
• Study of INCA 0186 in Subjects With Advanced Solid TumorsTerminatedNCT04989387Phase 1
• realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCLCompletedNCT04981795
• A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell LymphomaWithdrawnNCT04849715Phase 3
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.CompletedNCT04831996Phase 1
• To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.CompletedNCT04831944Phase 1
• Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsActive, not recruitingNCT04824092Phase 3
• To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)WithdrawnNCT04796922Phase 3
• To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550TerminatedNCT04674748Phase 1
• A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of ItacitinibTerminatedNCT04640025Phase 2
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Active, not recruitingNCT04509700Phase 2
• Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.CompletedNCT04463771Phase 2
• Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 InfectionNo longer availableNCT04355793
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsActive, not recruitingNCT04279847Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
• INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)WithdrawnNCT04203511Phase 3
• Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)CompletedNCT04048564
• A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic DermatitisCompletedNCT03920852Phase 1
• INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)WithdrawnNCT03920839Phase 1
• A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid TumorsCompletedNCT03910530Phase 1
• Expanded Access of Pemigatinib to Treat a Single Patient With Metastatic Pancreatic CancerNo longer availableNCT03906357
• Expanded Access Use of INCB052793 to Treat a Single Patient With MyelofibrosisNo longer availableNCT03906344
• Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic AnemiaNo longer availableNCT03906318
• Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell CarcinomaNo longer availableNCT03896815
• A Study of the Safety and Tolerability of INCB050465 in Pemphigus VulgarisWithdrawnNCT03780166Phase 2
• A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid TumorsCompletedNCT03762447Phase 1
• A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell LymphomaCompletedNCT03688152Phase 1
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• CALLS: CML and Ph+ALL Low Level Mutation Prevalence SurveyCompletedNCT03647215
• A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative ColitisWithdrawnNCT03627052Phase 2
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid TumorsCompletedNCT03589651Phase 1
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced MalignanciesTerminatedNCT03522142Phase 1
• A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"WithdrawnNCT03515785
• A Study of INCB059872 in Relapsed or Refractory Ewing SarcomaTerminatedNCT03514407Phase 1
• Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese SubjectsCompletedNCT03497273Phase 1
• INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)CompletedNCT03424122Phase 1
• Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)WithdrawnNCT03342352Phase 3
• GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host DiseaseTerminatedNCT03320642Phase 1
• A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedNCT03314922Phase 1
• A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic DermatitisCompletedNCT03257644Phase 1
• A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)CompletedNCT03235570Phase 1
• An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantApproved for marketingNCT03147742
• An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other MalignanciesTerminatedNCT03144661Phase 1
• A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell DiseaseTerminatedNCT03132324Phase 1
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid TumorsCompletedNCT03059823Phase 1
• Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)CompletedNCT03039114Phase 1
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
• Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)CompletedNCT02953704
• An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerCompletedNCT02917993Phase 1/2
• A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedNCT02723994Phase 2
• Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
• Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
• Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsTerminatedNCT02559492Phase 1
• INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
• Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
• A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1
• Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
• Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)CompletedNCT02252159
• INCB047986 in Rheumatoid ArthritisTerminatedNCT02151474Phase 2
• Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)TerminatedNCT02093429Phase 1/2
• An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesTerminatedNCT01929941Phase 1
• Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedNCT01905813Phase 1
• Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01858883Phase 1/2
• A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line ChemotherapyTerminatedNCT01685255Phase 2
• Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.CompletedNCT01641107Phase 2
• A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque PsoriasisCompletedNCT01634087Phase 2

← Incyte Corporation overview and focus areas